NCT05326620 National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
| NCT ID | NCT05326620 |
| Status | Recruiting |
| Phase | — |
| Sponsor | PROspective Renal Cancer Cohort Foundation |
| Condition | Renal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2023-01-19 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2023-01-19 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs) that provides an infrastructure for observational research and (randomized) interventional studies with the TwiCs (Trial within cohorts) design.
Eligibility Criteria
Inclusion Criteria: * newly diagnosed patients with RCC or synchronous metastatic RCC * metachronous metastasized RCC * age \>18 years * capable of understanding Dutch language Exclusion Criteria: * n/a
Contact & Investigator
Adriaan Bins, MD, PhD
PRINCIPAL INVESTIGATOR
Amsterdam UMC
Frequently Asked Questions
Who can join the NCT05326620 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05326620 currently recruiting?
Yes, NCT05326620 is actively recruiting participants. Contact the research team at h.yildirim@iknl.nl for enrollment information.
Where is the NCT05326620 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands, 's-Hertogenbosch, Netherlands, 's-Hertogenbosch, Netherlands, Amersfoort, Netherlands and 11 additional locations.
Who is sponsoring the NCT05326620 clinical trial?
NCT05326620 is sponsored by PROspective Renal Cancer Cohort Foundation. The principal investigator is Adriaan Bins, MD, PhD at Amsterdam UMC. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.